The latest Business updates from the science industry
Partnership to Develop Small Molecule Detection Instrument by Heather Hobbs
Product development company TTP plc and Camena Bioscience, a specialist in the profi ling of small molecules, such as metabolites, nutrients or medicines in liquid samples, are combining their skills to develop an instrument to monitor the health of cell cultures. The project to commercialise a proprietary small-molecule detection technology is led by Camena Bioscience which won co-funding from Innovate UK, the UK’s innovation agency, with GSK plc and The Centre for Process Innovation as further project
partners.TTP will lead the design and development of an analytical reader and housing for the biosensors.
Jana Voigt, COO of Camena Bioscience Jana Voight Stuart Lowe explained: “Existing
technologies only permit the monitoring of a few types of small molecules in cell culture, or typically require large, complex and expensive lab equipment. Camena Bioscience’s sensor technology
will extend the range of small molecules that can be monitored in cell culture, allow for simultaneous detection of multiple metabolites, and ensure that the new instrument provides rapid and accurate results from small samples of the culture medium.”
Stuart Lowe, Life Science Consultant at TTP said: “In recent years the Life Science Group at TTP has been driving innovation in the bioprocessing market. Camena Bioscience has an exciting and timely new technology – their instrument vision is complementary to much of the work that TTP has been undertaking in Desktop Biology, with the goal of democratising analysis through increased simplicity and smaller system footprint. We look forward to working with the consortium Camena Bioscience has built to capitalise on their sensor technology.”
46085pr@reply-direct.com
CERN Technology Underlies Next Generation Cancer Treatment
STFC and Advanced Oncotherapy are collaborating in the construction of a proton therapy assembly and test facility at STFC’s Daresbury Laboratory, that will build on the technology at the heart of the Large Hadron Collider (CERN Geneva)) to develop treatments for patients with cancer.
Proton beams targeted precisely at cancerous tumours will limit damage to surrounding organs or tissue, produce fewer side effects and also offer the potential for higher disease-free survival rates. This therapy is most often used to treat brain tumours in young children whose organs and tissues are still developing, or cancers adjacent to critical part of the body (liver, lung, head and neck, prostate, breast).
Advanced Oncotherapy said that its ‘LIGHT’ system, expected to be the fi rst commercially available linear proton accelerator, would be represent a milestone advancement in cancer therapy, with reduce construction costs and ability to provide hospitals and treatment centres with customisd treatment plans based on a wide range of energies.
UK Science Minister Sam Gyimah said: “Almost all of us have been affected by cancer in some way, whether that’s receiving treatment ourselves or through people we know who have battled the disease.
Commercial Success brings Queen’s Award to CDMO
Contract development and manufacturing organisation Cobra Biologics has received the Queen’s Award 2018 for Enterprise, International Trade category, in recognition of its commercial success in providing services to its global customer base.
The reception at Buckingham Palace will be followed by a presentation of the award by a representative of Her Majesty The Queen at Cobra’s UK facility later in the year.
The company has a 20 year track record of supporting the life science industry with contract development and manufacturing of biopharmaceuticals, from preclinical through to clinical trials and commercial supply and currently exports over 85% of its services from its facilities based in the UK and Sweden.
Cobra’s UK based GMP approved facility is a globally
recognised centre of excellence for the development and production of biological material to support both gene- and
immuno-therapy. In April 2017, Cobra announced a £15 million gene therapy expansion plan, to meet the increased demand from both plasmid DNA and viral vectors for Phase III and Commercial supply to support both existing and new customer requirements in the development of revolutionary disease therapies.
Chief Executive Peter Coleman, commented: “I am immensely proud of what Cobra has achieved over the last few years, culminating in the Queen’s Award. International Trade is vitally important for Cobra and the work that we do is challenging and requires a committed work force whose skills and dedication attract business from all over the world. I would like also to thank the Offi ce for Life Science, Innovate UK and the Department for International Trade for their support of our expansion plans in the UK.”
46377pr@reply-direct.com
Today’s investment will help develop the next generation of treatments and could take us one step closer to fi nding a cure, making a huge difference to millions of peoples’ lives.
“The UK remains a leading destination for science, research and innovation and has been home to many of the world’s greatest medical discoveries and development of treatments. Through the Government’s modern Industrial Strategy and Life Sciences Sector Deal, we are encouraging collaboration between industry, academia and business to ensure the UK remains at the forefront of the latest technologies and developments, building a Britain fi t for the future.”
Professor Susan Smith, Head of STFC’s Daresbury Laboratory, said the decision was recognition of the Laboratory’s world leading skills and experience in the fi eld of particle accelerators. “At STFC we are committed to developing accelerator technology and expertise to address the world’s key challenges, as well as to help businesses innovate to the benefi t of our society and our economy.”
46374pr@reply-direct.com
Ingenza Relocation Reflects Ambitious Growth Plans
John Mackenzie and Jaymin Amin
Ingenza is pleased to announce its relocation to Roslin Innovation Centre, a £30 million, multi-purpose research hub on the University of Edinburgh’s Easter Bush Campus. The centre offers 41,000 ft2 of fl exible laboratory and offi ce space, and Ingenza will occupy 11,000 ft2 on the top fl oor, with its own secure access to ensure security and confi dentiality.
The move, scheduled to take place in July 2018, will double Ingenza’s current footprint, preparing the company for its next phase of growth, as COO Jaymin Amin explained: “The UK bioeconomy is one of the strongest in the world and growing rapidly. The development of our inABLE® technology, which helps to improve the speed and predictability of bioengineering processes, has opened up new commercial opportunities, and the state-of-the-art laboratories offered by Roslin Innovation Centre will be an ideal location for us to expand our customer base in the bio-based chemicals, agrochemicals and biopharma sectors. This exciting move will provide a secure, world- class facility to support our aggressive growth plans, and will help to underpin our position as a global leader in the application of industrial biotechnology and synthetic biology.”
John Mackenzie, CEO of Roslin Innovation Centre, said: “We are looking forward to welcoming Ingenza, which will be our largest resident. Ingenza is recognised as one of the most dynamic European industrial biotech companies, and is a leader in this expanding sector. We already have a strong working bond with the company, which is so much more than a simple tenant/landlord relationship, and we very much look forward to increasing our Campus collaboration with such an innovative company.”
For more information, visit
www.ingenza.com.
46092pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36
